- Home
- BTBD vs INTS Comparison
BTBD vs INTS Comparison
Compare BTBD & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBD
- INTS
- Stock Information
- Founded
- BTBD 1987
- INTS 2012
- Country
- BTBD United States
- INTS United States
- Employees
- BTBD N/A
- INTS N/A
- Industry
- BTBD Restaurants
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- BTBD Consumer Discretionary
- INTS Health Care
- Exchange
- BTBD Nasdaq
- INTS Nasdaq
- Market Cap
- BTBD 9.1M
- INTS 8.4M
- IPO Year
- BTBD 2021
- INTS 2023
- Fundamental
- Price
- BTBD $1.84
- INTS $0.28
- Analyst Decision
- BTBD
- INTS Strong Buy
- Analyst Count
- BTBD 0
- INTS 4
- Target Price
- BTBD N/A
- INTS $4.50
- AVG Volume (30 Days)
- BTBD 6.7M
- INTS 4.4M
- Earning Date
- BTBD 08-19-2025
- INTS 08-07-2025
- Dividend Yield
- BTBD N/A
- INTS N/A
- EPS Growth
- BTBD N/A
- INTS N/A
- EPS
- BTBD N/A
- INTS N/A
- Revenue
- BTBD $14,533,449.00
- INTS N/A
- Revenue This Year
- BTBD N/A
- INTS N/A
- Revenue Next Year
- BTBD N/A
- INTS N/A
- P/E Ratio
- BTBD N/A
- INTS N/A
- Revenue Growth
- BTBD 1.58
- INTS N/A
- 52 Week Low
- BTBD $1.00
- INTS $0.19
- 52 Week High
- BTBD $5.60
- INTS $4.35
- Technical
- Relative Strength Index (RSI)
- BTBD 56.30
- INTS 43.62
- Support Level
- BTBD $1.66
- INTS $0.28
- Resistance Level
- BTBD $1.89
- INTS $0.32
- Average True Range (ATR)
- BTBD 0.15
- INTS 0.03
- MACD
- BTBD -0.01
- INTS 0.00
- Stochastic Oscillator
- BTBD 87.18
- INTS 35.94
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.